![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 3
2022
Wang, Michael L.; Jurczak, Wojciech; Jerkeman, Mats; Trotman, Judith; Zinzani, Pier L.; Belada, David; Boccomini, Carola; Flinn, Ian W.; Giri, Pratyush; Goy, Andre; Hamlin, Paul A.; Hermine, Olivier; Hernandez-Rivas, Jose-Angel; Hong, Xiaonan; Kim, Seok Jin; Lewis, David; Mishima, Yuko; Ozcan, Muhit; Perini, Guilherme F.; Pocock, Christopher; Song, Yuqin; Spurgeon, Stephen E.; Storring, John M.; Walewski, Jan; Zhu, Jun; Qin, Rui; Henninger, Todd; Deshpande, Sanjay; Howes, Angela; Le Gouill, Steven und Dreyling, Martin
(2022):
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
In: New England Journal of Medicine, Bd. 386, Nr. 26: S. 2482-2494
2020
Pott, Christiane; Sehn, Laurie H.; Belada, David; Gribben, John; Hoster, Eva; Kahl, Brad; Kehden, Britta; Nicolas-Virelizier, Emmanuelle; Spielewoy, Nathalie; Fingerle-Rowson, Guenter; Harbron, Chris; Mundt, Kirsten; Wassner-Fritsch, Elisabeth und Cheson, Bruce D.
(Februar 2020):
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
In: Leukemia, Bd. 34, Nr. 2: S. 522-32
2018
Trotman, Judith; Barrington, Sally F.; Belada, David; Meignan, Michel; MacEwan, Robert; Owen, Carolyn; Ptacnik, Vaclav; Rosta, Andras; Fingerle-Rowson, Günter R.; Zhu, Jiawen; Nielsen, Tina; Sahin, Deniz; Hiddemann, Wolfgang; Marcus, Robert E. und Davies, Andrew
(2018):
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 11: S. 1530-1542